The Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) conducted their latest Enforcement Webinar on November 19, 2012. During the webinar, OPDP gave stakeholders a chance to directly communicate with the Agency about clarifications or questions concerning recent Warning Letters and Untitled Letters issued by OPDP. This particular webinar covered Warning Letters and Untitled Letters issued from May 2012 through mid October 2012. You can download the slides that were discussed in this webinar by clicking the link below.
These focused webinars support OPDP's mission to protect the public health by assuring that prescription drug information is truthful, balanced, and accurately communicated.
Download Slides: OPDP Enforcement Actions Webinar – November 19, 2012 (PDF – 76KB)
More in Drugs
Drug Safety and Availability
Development & Approval Process (Drugs)
Drug Development Tools (DDT) Letters of Support Guidance Documents for Drug Applications Laws, Regulations, Policies and Procedures for Drug Applications What Are Drug Development Tools? How Drugs are Developed and Approved Development Resources Conducting Clinical Trials Forms & Submission Requirements Manufacturing CDER Small Business and Industry Assistance Drug Innovation Drug Development Tools Qualification Programs
Guidance, Compliance & Regulatory Information
Science & Research (Drugs)